MX343366B - Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica. - Google Patents
Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.Info
- Publication number
- MX343366B MX343366B MX2013003330A MX2013003330A MX343366B MX 343366 B MX343366 B MX 343366B MX 2013003330 A MX2013003330 A MX 2013003330A MX 2013003330 A MX2013003330 A MX 2013003330A MX 343366 B MX343366 B MX 343366B
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- methods
- neurological disease
- treating neurological
- src
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 3
- 208000025966 Neurological disease Diseases 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
- C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
- C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38743910P | 2010-09-28 | 2010-09-28 | |
| PCT/US2011/053764 WO2012050921A2 (en) | 2010-09-28 | 2011-09-28 | Nd2 peptides and methods of treating neurological disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013003330A MX2013003330A (es) | 2013-09-26 |
| MX343366B true MX343366B (es) | 2016-11-01 |
Family
ID=45938878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003330A MX343366B (es) | 2010-09-28 | 2011-09-28 | Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9073976B2 (enExample) |
| EP (1) | EP2621945B1 (enExample) |
| JP (1) | JP6073230B2 (enExample) |
| KR (1) | KR101893473B1 (enExample) |
| CN (1) | CN103282379B (enExample) |
| AU (1) | AU2011314074B2 (enExample) |
| BR (1) | BR112013007557A2 (enExample) |
| CA (1) | CA2812948C (enExample) |
| DK (1) | DK2621945T3 (enExample) |
| IL (1) | IL225464B (enExample) |
| MX (1) | MX343366B (enExample) |
| RU (1) | RU2607033C2 (enExample) |
| SG (1) | SG189104A1 (enExample) |
| UA (1) | UA114592C2 (enExample) |
| WO (1) | WO2012050921A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA123820C2 (uk) * | 2014-05-28 | 2021-06-09 | Ноно Інк. | Хлоридна сіль пептиду tat-nr2b9c |
| CN109072242A (zh) * | 2016-02-23 | 2018-12-21 | 科罗拉多州立大学董事会法人团体 | 用于治疗神经损伤的基于肽的方法 |
| US11229675B2 (en) * | 2016-04-27 | 2022-01-25 | Biocells (Beijing) Biotech Co., Ltd. | Therapeutic peptides for excitatory neurotoxicity-related injuries |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CN112679595B (zh) * | 2020-04-10 | 2022-11-01 | 南京市儿童医院 | 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2281129T3 (es) * | 1997-08-12 | 2007-09-16 | Bristol-Myers Squibb Company | Canales de potasio kcnq y procedimientos para su modulacion. |
| CA2368229A1 (en) * | 1999-03-19 | 2000-09-28 | Craig A. Rosen | 50 human secreted proteins |
| NZ527302A (en) * | 2001-01-05 | 2006-10-27 | Abgenix Inc | Antibodies to insulin-like growth factor I receptor |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| EP1551424B1 (en) * | 2002-09-04 | 2015-07-01 | Arrowhead Research Corporation | Treatment of chronic neuropathic pain by admistration of dsrna |
| US8003609B2 (en) * | 2004-03-30 | 2011-08-23 | The Hospital For Sick Children | Method for ameliorating pain by modification of NMDA receptors through inhibition of Src |
| US7425540B2 (en) * | 2004-03-30 | 2008-09-16 | The Hospital For Sick Children | Method for modification of NMDA receptors through inhibition of Src |
| EP1912680B1 (en) * | 2005-06-15 | 2014-11-26 | The Ohio State University Research Foundation | Her-2 peptides |
| ES2446292T3 (es) * | 2007-03-02 | 2014-03-07 | Nono Inc. | Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N |
-
2011
- 2011-09-28 WO PCT/US2011/053764 patent/WO2012050921A2/en not_active Ceased
- 2011-09-28 AU AU2011314074A patent/AU2011314074B2/en not_active Ceased
- 2011-09-28 RU RU2013119830A patent/RU2607033C2/ru active
- 2011-09-28 BR BR112013007557-0A patent/BR112013007557A2/pt not_active Application Discontinuation
- 2011-09-28 KR KR1020137010823A patent/KR101893473B1/ko not_active Expired - Fee Related
- 2011-09-28 UA UAA201305474A patent/UA114592C2/uk unknown
- 2011-09-28 JP JP2013530433A patent/JP6073230B2/ja not_active Expired - Fee Related
- 2011-09-28 CN CN201180047059.0A patent/CN103282379B/zh not_active Expired - Fee Related
- 2011-09-28 DK DK11833072.9T patent/DK2621945T3/en active
- 2011-09-28 EP EP11833072.9A patent/EP2621945B1/en active Active
- 2011-09-28 CA CA2812948A patent/CA2812948C/en active Active
- 2011-09-28 MX MX2013003330A patent/MX343366B/es active IP Right Grant
- 2011-09-28 SG SG2013022397A patent/SG189104A1/en unknown
-
2013
- 2013-03-15 US US13/842,848 patent/US9073976B2/en active Active
- 2013-03-24 IL IL225464A patent/IL225464B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012050921A2 (en) | 2012-04-19 |
| CA2812948A1 (en) | 2012-04-19 |
| MX2013003330A (es) | 2013-09-26 |
| JP2014505655A (ja) | 2014-03-06 |
| IL225464A0 (en) | 2013-06-27 |
| CN103282379A (zh) | 2013-09-04 |
| UA114592C2 (uk) | 2017-07-10 |
| SG189104A1 (en) | 2013-05-31 |
| DK2621945T3 (en) | 2018-05-22 |
| RU2013119830A (ru) | 2014-11-10 |
| US20140274906A1 (en) | 2014-09-18 |
| US9073976B2 (en) | 2015-07-07 |
| AU2011314074A1 (en) | 2013-05-09 |
| AU2011314074B2 (en) | 2015-11-12 |
| CA2812948C (en) | 2019-01-22 |
| CN103282379B (zh) | 2016-01-06 |
| KR101893473B1 (ko) | 2018-08-30 |
| EP2621945B1 (en) | 2018-04-11 |
| RU2607033C2 (ru) | 2017-01-10 |
| KR20140048070A (ko) | 2014-04-23 |
| IL225464B (en) | 2018-03-29 |
| BR112013007557A2 (pt) | 2021-05-11 |
| JP6073230B2 (ja) | 2017-02-01 |
| EP2621945A2 (en) | 2013-08-07 |
| WO2012050921A3 (en) | 2012-07-05 |
| EP2621945A4 (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161656A (en) | Therapeutic use of diaminophenothiazines | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| IN2015DN00376A (enExample) | ||
| MY163275A (en) | Ibat inhibitors for the treatment of liver diseases | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| IN2014DN00288A (enExample) | ||
| IN2014DN00286A (enExample) | ||
| IN2014MN00093A (enExample) | ||
| IN2015DN00450A (enExample) | ||
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX367341B (es) | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. | |
| WO2014031928A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| IN2014MN01378A (enExample) | ||
| PH12013502620A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
| WO2012015758A3 (en) | Methods of treating pain | |
| MX2015007479A (es) | Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas. | |
| MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| IN2012DN02471A (enExample) | ||
| WO2014031936A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
| IN2012DN05186A (enExample) | ||
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| WO2013055385A3 (en) | Methods of treating age related disorders | |
| ZA202002103B (en) | Compounds as mpges-1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |